HEPNET
LIVE

Serial Number

97855612

Owner

E-Therapeutics Plc

Attorney

Anna King

Filing Date

Mar 24, 2023

Add to watchlist:

No watchlists yet
View on USPTO

HEPNET Trademark

Serial Number: 97855612 • Registration: 7575493

HEPNET is a trademark filed by E-Therapeutics Plc on March 24, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

E-Therapeutics Plc (13 trademarks)

Oxfordshire OX298LN , GB

Entity Type: 99

Trademark Details

Filing Date

March 24, 2023

Registration Date

November 26, 2024

Published for Opposition

March 12, 2024

Goods & Services

Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid

Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery

Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation

Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2024 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Nov 5, 2024 DP1B
NOTICE OF ALLOWANCE CANCELLED
Nov 4, 2024 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Nov 4, 2024 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 7, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 12, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 12, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 21, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 2, 2024 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 30, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 30, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 30, 2024 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jan 30, 2024 GPRN
PRIORITY ACTION E-MAILED
Jan 30, 2024 GPRA
PRIORITY ACTION WRITTEN
Jan 30, 2024 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 26, 2023 CRFA
ASSIGNED TO LIE
Dec 26, 2023 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 31, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 18, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 18, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 18, 2023 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 27, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 25, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 16, 2023 NWOS
NEW APPLICATION ENTERED
Mar 28, 2023 NWAP